Latest Conference Articles

Copernicus and Galileo trials: Effect of time since diagnosis on BCVA outcomes in CRVO

Copernicus and Galileo trials: Effect of time since diagnosis on BCVA outcomes in CRVO

June 30th 2022

Retina World Congress

Dilsher Dhoot, MD, discusses the post hoc analysis of the Copernicus and Galileo trials, which investigated if a delay in treatment would affect visual acuity gains or change in anatomy.

Phase 3 Archway end-of-trial results: Port Delivery System is noninferior to monthly ranibizumab

Phase 3 Archway end-of-trial results: Port Delivery System is noninferior to monthly ranibizumab

June 29th 2022

Retina World Congress

Aleksandra Rachitskaya, MD, discussed the Phase 3 Archway end-of-trial results for the investigation of the Port Delivery System with ranibizumab in neovascular AMD.

Morphologic features of vitreous cortex hyalocyte captured with OCT

Morphologic features of vitreous cortex hyalocyte captured with OCT

June 28th 2022

ARVO

Richard Rosen, MD, shares insights on how imaging can capture hyalocytes and their movement without the use of dyes.

Expanding the therapeutic arsenal for noninfectious uveitis, uveitic macular edema

Expanding the therapeutic arsenal for noninfectious uveitis, uveitic macular edema

June 23rd 2022

Retina World Congress

Steven Yeh, MD, provides a brief overview of available therapies for noninfectious uveitis and uveitis macular edema.

Phase 3 investigation of OPT-302 combination therapy assess superiority in mean BCVA over anti-VEGF-A monotherapy

Phase 3 investigation of OPT-302 combination therapy assess superiority in mean BCVA over anti-VEGF-A monotherapy

June 23rd 2022

Retina World Congress

David Boyer, MD, discusses the Phase 3 investigation for OPT-302 combination therapy for wet AMD.

Measuring retinal blood flow biomarkers using OCT Doppler

Measuring retinal blood flow biomarkers using OCT Doppler

June 14th 2022

ARVO

The study assesses retinal blood biomarkers using a new prototype OCT, aiming to measure retinal biomarkers such as blood flow volume, average velocity, and vessel diameter with a new prototype.

Hypersonic vitrectomy: Novel technology for vitreous removal

Hypersonic vitrectomy: Novel technology for vitreous removal

June 9th 2022

Retina World Congress

Though the speed of traditional guillotine cutters has increased significantly in recent years, there are certain limitations. With the advent of hypersonic vitrectomy, Sunir J. Garg, MD, FACS, explains how retinal surgeons can remove the vitreous gel with more efficiency.

Carl Regillo, MD, outlines latest results of KSI-301 clinical trial

Carl Regillo, MD, outlines latest results of KSI-301 clinical trial

June 7th 2022

Retina World Congress

While the DAZZLE trial failed to meet its primary endpoint, KSI-301 demonstrated good initial visual gains and anatomic effects as well as positive durability.

YOSEMITE and RHINE trials yield durability, retinal fluid reduction, DME resolution with faricimab

YOSEMITE and RHINE trials yield durability, retinal fluid reduction, DME resolution with faricimab

June 6th 2022

Retina World Congress

In the study, the faricimab molecule, which is a combined anti-Ang2 and anti-VEGF, performed better than the aflibercept drug in many different ways. Rishi P. Singh, MD, FASRS, summarizes some of these key findings.